Alex Hogan/STAT

STAT+ | Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

Highly unusual "compassionate use" trial for Lilly's weight loss drug retatrutide raises questions over patient identity.

By Lizzy Lawrence

STAT+ | A sweeping new AI to detect heart conditions is coming to OpenEvidence

FDA-approved AI tool, EchoNext by Pathway Labs, can predict seven types of heart conditions from an EKG , will be available via OpenEvidence search engine.

By Mario Aguilar

Trump administration targets disability integration mandate in DOJ memo

A new Justice Department memo seeks could upend disability laws that prioritize people with disabilities receiving care in their community, rather than at institutions.

By O. Rose Broderick

Adobe

Opinion: Ending birthright citizenship could be a public health disaster

Birthright citizenship ends up intersecting with health care in a surprising number of ways, expert writes.

By Rachel E. Fabi

STAT+ | Cadence raises $100 million to automate chronic disease care with regulated AI

Cadence, a digital health company that cares for patients with chronic conditions, has raised $100 million as it seeks to expand its footprint and use AI for automation.

By Mario Aguilar

STAT+ | Want high-quality generic drugs? One expert has ideas on how consumers can trust their supply

Kevin Schulman of Stanford University School argues the FDA should encourage testing by independent, accredited labs.

By Ed Silverman

Adobe

Opinion: The Catch-22 for disabled workers hidden in Medicaid’s new work requirements

Medicaid’s new work requirements could force disabled people to choose between work and care.

By Maria Town and Nicole Jorwic

STAT+ | Gene-editing startup launches with $230 million and a Chinese licensing deal

Serapha Bio is entering a crowded field of firms hoping to develop treatments for the genetic disorder AATD.

By Allison DeAngelis